Sunesis Pharmaceuticals, Inc. Logo

Sunesis Pharmaceuticals, Inc. Risk Report

Generated on July 16, 2025

1

Risks

Summary

πŸ›‘οΈ Financial & Liquidity

Sunesis Pharmaceuticals has faced financial challenges, especially evident in the past performance of its stock and associated entities. Viracta's stock plunged to a 52-week low of $0.08, reflecting significant financial strain. Strategic mergers and financial decisions highlight their ongoing efforts to stabilize and grow.

  • Viracta Therapeutics, post-merger with Sunesis, experienced a stock value plunge to $0.08 on πŸ—“ February 3, 2025.
  • The merger with Viracta Therapeutics was finalized, along with a $65 million private placement πŸ—“ on February 25, 2021.

βš–οΈ Legal & Regulatory

No significant legal or regulatory issues have been reported for Sunesis Pharmaceuticals, indicating compliance with industry standards.

πŸ‘₯ Labor & Workforce

No notable labor or workforce-related events were found in the data provided for Sunesis Pharmaceuticals.

πŸ—οΈ Operational & Business Continuity

Sunesis Pharmaceuticals experienced operational challenges impacting business continuity. The cessation of vosaroxin in Europe marked a critical operational decision affecting their European market strategy.

  • Sunesis Pharmaceuticals terminated its European leukemia drug, vosaroxin, operations πŸ—“ on May 2, 2017.

πŸ“œ Innovation & R&D

Sunesis Pharmaceuticals maintains a focus on innovation and R&D, as seen in their external collaborations and developments. This remains a key driver for future opportunities in the biotech sector.

  • The company received FDA fast track designation for vosaroxin in AML, marking a significant milestone πŸ—“ on February 23, 2011.
  • Clinical updates were announced on the vecabrutinib program, representing ongoing R&D efforts πŸ—“ on June 23, 2020.

πŸ… Awards & Recognition

No awards or recognition were noted in the current data for Sunesis Pharmaceuticals.

News & Media

Stay informed with real-time news signals across financial, legal, and operational domains.

Profile

Founded Year
1987
Social Media